In addition, pre-treatment with 500 nM BPTES for 48 h did not increase the sensitivities of ß-lap-responsive, NQO1-expressing KRAS wild-type lung, breast, or pancreatic cancer cell lines, consistent with reported literature [8, 30]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.